We’ll be at ASH24, sharing latest Phase II clinical data on our oral small molecule p300/CBP inhibitor, inobrodib. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/
We’ll be at #ASH24. Presentation on our novel MoA oral drug, to treat multiple myeloma. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/ Many thanks @DrEmmaSearle, The Christie NHS Fdn Trust.
We are delighted to collaborate with the American Cancer Society CAN, gaining insights on needs and preferences of people with multiple myeloma. @ACSCAN
We’ll be at ASH24, sharing latest Phase II clinical data on our oral small molecule p300/CBP inhibitor, inobrodib. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/
We’ll be at #ASH24. Presentation on our novel MoA oral drug, to treat multiple myeloma. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/ Many thanks @DrEmmaSearle, The Christie NHS Fdn Trust.
We are delighted to collaborate with the American Cancer Society CAN, gaining insights on needs and preferences of people with multiple myeloma. @ACSCAN
We’ll be at ASH24, sharing latest Phase II clinical data on our oral small molecule p300/CBP inhibitor, inobrodib. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/
We’ll be at #ASH24. Presentation on our novel MoA oral drug, to treat multiple myeloma. See: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/ Many thanks @DrEmmaSearle, The Christie NHS Fdn Trust.
We are delighted to collaborate with the American Cancer Society CAN, gaining insights on needs and preferences of people with multiple myeloma. @ACSCAN
